Gene symbol: INS

Also known as: IDDM; ILPR; IRDN; IDDM1; IDDM2; PNDM4; MODY10

Organism: Homo sapiens

Summary: This gene encodes insulin, a peptide hormone that plays a vital role in the regulation of carbohydrate and lipid metabolism. After removal of the precursor signal peptide, proinsulin is post-translationally cleaved into three peptides: the B chain and A chain peptides, which are covalently linked via two disulfide bonds to form insulin, and C-peptide. Binding of insulin to the insulin receptor (INSR) stimulates glucose uptake. A multitude of mutant alleles with phenotypic effects have been identified, including insulin-dependent diabetes mellitus, permanent neonatal diabetes diabetes mellitus, maturity-onset diabetes of the young type 10 and hyperproinsulinemia. There is a read-through gene, INS-IGF2, which overlaps with this gene at the 5' region and with the IGF2 gene at the 3' region. [provided by RefSeq, May 2020]

NCBI gene ID: 3630 Ensembl:ENSG00000254647 MIM:176730 AllianceGenome:HGNC:6081


GO Annotation


Category Term ID Term description
Process GO:0001101 Response to acid chemical
Process GO:0001558 Regulation of cell growth
Process GO:0001775 Cell activation
Process GO:0001817 Regulation of cytokine production
Process GO:0001819 Positive regulation of cytokine production
Process GO:0001932 Regulation of protein phosphorylation
Process GO:0001934 Positive regulation of protein phosphorylation
Process GO:0002376 Immune system process
Process GO:0002526 Acute inflammatory response
Process GO:0002673 Regulation of acute inflammatory response
Process GO:0002674 Negative regulation of acute inflammatory response
Process GO:0002682 Regulation of immune system process
Process GO:0002683 Negative regulation of immune system process
Process GO:0002697 Regulation of immune effector process
Process GO:0002698 Negative regulation of immune effector process
Process GO:0002791 Regulation of peptide secretion
Process GO:0002793 Positive regulation of peptide secretion
Process GO:0002831 Regulation of response to biotic stimulus
Process GO:0002832 Negative regulation of response to biotic stimulus
Process GO:0003008 System process
Process GO:0003013 Circulatory system process
Process GO:0003018 Vascular process in circulatory system
Process GO:0005975 Carbohydrate metabolic process
Process GO:0005979 Regulation of glycogen biosynthetic process
Process GO:0005981 Regulation of glycogen catabolic process
Process GO:0005996 Monosaccharide metabolic process
Process GO:0006006 Glucose metabolic process
Process GO:0006109 Regulation of carbohydrate metabolic process
Process GO:0006110 Regulation of glycolytic process
Process GO:0006111 Regulation of gluconeogenesis
Process GO:0006140 Regulation of nucleotide metabolic process
Process GO:0006355 Regulation of transcription, DNA-templated
Process GO:0006521 Regulation of cellular amino acid metabolic process
Process GO:0006950 Response to stress
Process GO:0006952 Defense response
Process GO:0006953 Acute-phase response
Process GO:0006954 Inflammatory response
Process GO:0007088 Regulation of mitotic nuclear division
Process GO:0007154 Cell communication
Process GO:0007165 Signal transduction
Process GO:0007166 Cell surface receptor signaling pathway
Process GO:0007167 Enzyme-linked receptor protein signaling pathway
Process GO:0007169 Transmembrane receptor protein tyrosine kinase signaling pathway
Process GO:0007186 G protein-coupled receptor signaling pathway
Process GO:0007263 Nitric oxide mediated signal transduction
Process GO:0007267 Cell-cell signaling
Process GO:0007346 Regulation of mitotic cell cycle
Process GO:0008015 Blood circulation
Process GO:0008152 Metabolic process
Process GO:0008284 Positive regulation of cell population proliferation
Process GO:0008286 Insulin receptor signaling pathway
Process GO:0009611 Response to wounding
Process GO:0009719 Response to endogenous stimulus
Process GO:0009725 Response to hormone
Process GO:0009889 Regulation of biosynthetic process
Process GO:0009890 Negative regulation of biosynthetic process
Process GO:0009891 Positive regulation of biosynthetic process
Process GO:0009892 Negative regulation of metabolic process
Process GO:0009893 Positive regulation of metabolic process
Process GO:0009894 Regulation of catabolic process
Process GO:0009895 Negative regulation of catabolic process
Process GO:0009896 Positive regulation of catabolic process
Process GO:0009966 Regulation of signal transduction
Process GO:0009967 Positive regulation of signal transduction
Process GO:0009968 Negative regulation of signal transduction
Process GO:0009987 Cellular process
Process GO:0010033 Response to organic substance
Process GO:0010243 Response to organonitrogen compound
Process GO:0010468 Regulation of gene expression
Process GO:0010556 Regulation of macromolecule biosynthetic process
Process GO:0010557 Positive regulation of macromolecule biosynthetic process
Process GO:0010562 Positive regulation of phosphorus metabolic process
Process GO:0010564 Regulation of cell cycle process
Process GO:0010565 Regulation of cellular ketone metabolic process
Process GO:0010604 Positive regulation of macromolecule metabolic process
Process GO:0010605 Negative regulation of macromolecule metabolic process
Process GO:0010628 Positive regulation of gene expression
Process GO:0010629 Negative regulation of gene expression
Process GO:0010638 Positive regulation of organelle organization
Process GO:0010646 Regulation of cell communication
Process GO:0010647 Positive regulation of cell communication
Process GO:0010648 Negative regulation of cell communication
Process GO:0010675 Regulation of cellular carbohydrate metabolic process
Process GO:0010676 Positive regulation of cellular carbohydrate metabolic process
Process GO:0010677 Negative regulation of cellular carbohydrate metabolic process
Process GO:0010749 Regulation of nitric oxide mediated signal transduction
Process GO:0010750 Positive regulation of nitric oxide mediated signal transduction
Process GO:0010817 Regulation of hormone levels
Process GO:0010827 Regulation of glucose transmembrane transport
Process GO:0010828 Positive regulation of glucose transmembrane transport
Process GO:0010906 Regulation of glucose metabolic process
Process GO:0010907 Positive regulation of glucose metabolic process
Process GO:0010941 Regulation of cell death
Process GO:0010962 Regulation of glucan biosynthetic process
Process GO:0014066 Regulation of phosphatidylinositol 3-kinase signaling
Process GO:0014068 Positive regulation of phosphatidylinositol 3-kinase signaling
Process GO:0016043 Cellular component organization
Process GO:0019216 Regulation of lipid metabolic process
Process GO:0019217 Regulation of fatty acid metabolic process
Process GO:0019219 Regulation of nucleobase-containing compound metabolic process
Process GO:0019220 Regulation of phosphate metabolic process
Process GO:0019222 Regulation of metabolic process
Process GO:0019318 Hexose metabolic process
Process GO:0019932 Second-messenger-mediated signaling
Process GO:0019934 cGMP-mediated signaling
Process GO:0019935 Cyclic-nucleotide-mediated signaling
Process GO:0022898 Regulation of transmembrane transporter activity
Process GO:0023051 Regulation of signaling
Process GO:0023052 Signaling
Process GO:0023056 Positive regulation of signaling
Process GO:0023057 Negative regulation of signaling
Process GO:0030030 Cell projection organization
Process GO:0030162 Regulation of proteolysis
Process GO:0030307 Positive regulation of cell growth
Process GO:0030334 Regulation of cell migration
Process GO:0030335 Positive regulation of cell migration
Process GO:0031323 Regulation of cellular metabolic process
Process GO:0031324 Negative regulation of cellular metabolic process
Process GO:0031325 Positive regulation of cellular metabolic process
Process GO:0031326 Regulation of cellular biosynthetic process
Process GO:0031327 Negative regulation of cellular biosynthetic process
Process GO:0031328 Positive regulation of cellular biosynthetic process
Process GO:0031329 Regulation of cellular catabolic process
Process GO:0031330 Negative regulation of cellular catabolic process
Process GO:0031331 Positive regulation of cellular catabolic process
Process GO:0031344 Regulation of cell projection organization
Process GO:0031346 Positive regulation of cell projection organization
Process GO:0031347 Regulation of defense response
Process GO:0031348 Negative regulation of defense response
Process GO:0031399 Regulation of protein modification process
Process GO:0031401 Positive regulation of protein modification process
Process GO:0031952 Regulation of protein autophosphorylation
Process GO:0031954 Positive regulation of protein autophosphorylation
Process GO:0032101 Regulation of response to external stimulus
Process GO:0032102 Negative regulation of response to external stimulus
Process GO:0032147 Activation of protein kinase activity
Process GO:0032148 Activation of protein kinase B activity
Process GO:0032409 Regulation of transporter activity
Process GO:0032501 Multicellular organismal process
Process GO:0032768 Regulation of monooxygenase activity
Process GO:0032770 Positive regulation of monooxygenase activity
Process GO:0032868 Response to insulin
Process GO:0032869 Cellular response to insulin stimulus
Process GO:0032870 Cellular response to hormone stimulus
Process GO:0032879 Regulation of localization
Process GO:0032880 Regulation of protein localization
Process GO:0032881 Regulation of polysaccharide metabolic process
Process GO:0032885 Regulation of polysaccharide biosynthetic process
Process GO:0033043 Regulation of organelle organization
Process GO:0033238 Regulation of cellular amine metabolic process
Process GO:0033500 Carbohydrate homeostasis
Process GO:0033674 Positive regulation of kinase activity
Process GO:0033860 Regulation of NAD(P)H oxidase activity
Process GO:0033861 Negative regulation of NAD(P)H oxidase activity
Process GO:0034762 Regulation of transmembrane transport
Process GO:0034764 Positive regulation of transmembrane transport
Process GO:0035150 Regulation of tube size
Process GO:0035296 Regulation of tube diameter
Process GO:0035556 Intracellular signal transduction
Process GO:0038060 Nitric oxide-cGMP-mediated signaling pathway
Process GO:0040008 Regulation of growth
Process GO:0040012 Regulation of locomotion
Process GO:0040017 Positive regulation of locomotion
Process GO:0042060 Wound healing
Process GO:0042110 T cell activation
Process GO:0042127 Regulation of cell population proliferation
Process GO:0042176 Regulation of protein catabolic process
Process GO:0042177 Negative regulation of protein catabolic process
Process GO:0042221 Response to chemical
Process GO:0042311 Vasodilation
Process GO:0042325 Regulation of phosphorylation
Process GO:0042327 Positive regulation of phosphorylation
Process GO:0042592 Homeostatic process
Process GO:0042593 Glucose homeostasis
Process GO:0042981 Regulation of apoptotic process
Process GO:0043066 Negative regulation of apoptotic process
Process GO:0043067 Regulation of programmed cell death
Process GO:0043069 Negative regulation of programmed cell death
Process GO:0043085 Positive regulation of catalytic activity
Process GO:0043086 Negative regulation of catalytic activity
Process GO:0043200 Response to amino acid
Process GO:0043255 Regulation of carbohydrate biosynthetic process
Process GO:0043408 Regulation of MAPK cascade
Process GO:0043410 Positive regulation of MAPK cascade
Process GO:0043434 Response to peptide hormone
Process GO:0043467 Regulation of generation of precursor metabolites and energy
Process GO:0043470 Regulation of carbohydrate catabolic process
Process GO:0043471 Regulation of cellular carbohydrate catabolic process
Process GO:0043549 Regulation of kinase activity
Process GO:0044092 Negative regulation of molecular function
Process GO:0044093 Positive regulation of molecular function
Process GO:0044238 Primary metabolic process
Process GO:0044281 Small molecule metabolic process
Process GO:0045088 Regulation of innate immune response
Process GO:0045321 Leukocyte activation
Process GO:0045595 Regulation of cell differentiation
Process GO:0045597 Positive regulation of cell differentiation
Process GO:0045598 Regulation of fat cell differentiation
Process GO:0045600 Positive regulation of fat cell differentiation
Process GO:0045721 Negative regulation of gluconeogenesis
Process GO:0045725 Positive regulation of glycogen biosynthetic process
Process GO:0045787 Positive regulation of cell cycle
Process GO:0045818 Negative regulation of glycogen catabolic process
Process GO:0045821 Positive regulation of glycolytic process
Process GO:0045824 Negative regulation of innate immune response
Process GO:0045833 Negative regulation of lipid metabolic process
Process GO:0045834 Positive regulation of lipid metabolic process
Process GO:0045840 Positive regulation of mitotic nuclear division
Process GO:0045859 Regulation of protein kinase activity
Process GO:0045860 Positive regulation of protein kinase activity
Process GO:0045861 Negative regulation of proteolysis
Process GO:0045912 Negative regulation of carbohydrate metabolic process
Process GO:0045913 Positive regulation of carbohydrate metabolic process
Process GO:0045922 Negative regulation of fatty acid metabolic process
Process GO:0045927 Positive regulation of growth
Process GO:0045935 Positive regulation of nucleobase-containing compound metabolic process
Process GO:0045937 Positive regulation of phosphate metabolic process
Process GO:0045981 Positive regulation of nucleotide metabolic process
Process GO:0046324 Regulation of glucose import
Process GO:0046326 Positive regulation of glucose import
Process GO:0046626 Regulation of insulin receptor signaling pathway
Process GO:0046628 Positive regulation of insulin receptor signaling pathway
Process GO:0046631 Alpha-beta T cell activation
Process GO:0046649 Lymphocyte activation
Process GO:0046883 Regulation of hormone secretion
Process GO:0046887 Positive regulation of hormone secretion
Process GO:0046889 Positive regulation of lipid biosynthetic process
Process GO:0046890 Regulation of lipid biosynthetic process
Process GO:0048167 Regulation of synaptic plasticity
Process GO:0048518 Positive regulation of biological process
Process GO:0048519 Negative regulation of biological process
Process GO:0048521 Negative regulation of behavior
Process GO:0048522 Positive regulation of cellular process
Process GO:0048523 Negative regulation of cellular process
Process GO:0048583 Regulation of response to stimulus
Process GO:0048584 Positive regulation of response to stimulus
Process GO:0048585 Negative regulation of response to stimulus
Process GO:0048878 Chemical homeostasis
Process GO:0050708 Regulation of protein secretion
Process GO:0050709 Negative regulation of protein secretion
Process GO:0050714 Positive regulation of protein secretion
Process GO:0050727 Regulation of inflammatory response
Process GO:0050728 Negative regulation of inflammatory response
Process GO:0050776 Regulation of immune response
Process GO:0050777 Negative regulation of immune response
Process GO:0050789 Regulation of biological process
Process GO:0050790 Regulation of catalytic activity
Process GO:0050793 Regulation of developmental process
Process GO:0050794 Regulation of cellular process
Process GO:0050795 Regulation of behavior
Process GO:0050803 Regulation of synapse structure or activity
Process GO:0050804 Modulation of chemical synaptic transmission
Process GO:0050806 Positive regulation of synaptic transmission
Process GO:0050807 Regulation of synapse organization
Process GO:0050877 Nervous system process
Process GO:0050890 Cognition
Process GO:0050896 Response to stimulus
Process GO:0050994 Regulation of lipid catabolic process
Process GO:0050995 Negative regulation of lipid catabolic process
Process GO:0050999 Regulation of nitric-oxide synthase activity
Process GO:0051000 Positive regulation of nitric-oxide synthase activity
Process GO:0051046 Regulation of secretion
Process GO:0051047 Positive regulation of secretion
Process GO:0051048 Negative regulation of secretion
Process GO:0051049 Regulation of transport
Process GO:0051050 Positive regulation of transport
Process GO:0051051 Negative regulation of transport
Process GO:0051090 Regulation of DNA-binding transcription factor activity
Process GO:0051091 Positive regulation of DNA-binding transcription factor activity
Process GO:0051092 Positive regulation of NF-kappaB transcription factor activity
Process GO:0051094 Positive regulation of developmental process
Process GO:0051128 Regulation of cellular component organization
Process GO:0051130 Positive regulation of cellular component organization
Process GO:0051171 Regulation of nitrogen compound metabolic process
Process GO:0051172 Negative regulation of nitrogen compound metabolic process
Process GO:0051173 Positive regulation of nitrogen compound metabolic process
Process GO:0051174 Regulation of phosphorus metabolic process
Process GO:0051222 Positive regulation of protein transport
Process GO:0051223 Regulation of protein transport
Process GO:0051224 Negative regulation of protein transport
Process GO:0051239 Regulation of multicellular organismal process
Process GO:0051240 Positive regulation of multicellular organismal process
Process GO:0051241 Negative regulation of multicellular organismal process
Process GO:0051246 Regulation of protein metabolic process
Process GO:0051247 Positive regulation of protein metabolic process
Process GO:0051248 Negative regulation of protein metabolic process
Process GO:0051252 Regulation of RNA metabolic process
Process GO:0051338 Regulation of transferase activity
Process GO:0051341 Regulation of oxidoreductase activity
Process GO:0051347 Positive regulation of transferase activity
Process GO:0051353 Positive regulation of oxidoreductase activity
Process GO:0051354 Negative regulation of oxidoreductase activity
Process GO:0051716 Cellular response to stimulus
Process GO:0051726 Regulation of cell cycle
Process GO:0051783 Regulation of nuclear division
Process GO:0051785 Positive regulation of nuclear division
Process GO:0051896 Regulation of protein kinase B signaling
Process GO:0051897 Positive regulation of protein kinase B signaling
Process GO:0055088 Lipid homeostasis
Process GO:0055089 Fatty acid homeostasis
Process GO:0060255 Regulation of macromolecule metabolic process
Process GO:0060259 Regulation of feeding behavior
Process GO:0060263 Regulation of respiratory burst
Process GO:0060264 Regulation of respiratory burst involved in inflammatory response
Process GO:0060266 Negative regulation of respiratory burst involved in inflammatory response
Process GO:0060267 Positive regulation of respiratory burst
Process GO:0060268 Negative regulation of respiratory burst
Process GO:0060284 Regulation of cell development
Process GO:0060341 Regulation of cellular localization
Process GO:0060548 Negative regulation of cell death
Process GO:0062012 Regulation of small molecule metabolic process
Process GO:0062013 Positive regulation of small molecule metabolic process
Process GO:0062014 Negative regulation of small molecule metabolic process
Process GO:0065007 Biological regulation
Process GO:0065008 Regulation of biological quality
Process GO:0065009 Regulation of molecular function
Process GO:0070201 Regulation of establishment of protein localization
Process GO:0070873 Regulation of glycogen metabolic process
Process GO:0070874 Negative regulation of glycogen metabolic process
Process GO:0070875 Positive regulation of glycogen metabolic process
Process GO:0070887 Cellular response to chemical stimulus
Process GO:0071310 Cellular response to organic substance
Process GO:0071375 Cellular response to peptide hormone stimulus
Process GO:0071417 Cellular response to organonitrogen compound
Process GO:0071495 Cellular response to endogenous stimulus
Process GO:0071704 Organic substance metabolic process
Process GO:0071840 Cellular component organization or biogenesis
Process GO:0080090 Regulation of primary metabolic process
Process GO:0080134 Regulation of response to stress
Process GO:0080135 Regulation of cellular response to stress
Process GO:0090066 Regulation of anatomical structure size
Process GO:0090068 Positive regulation of cell cycle process
Process GO:0090087 Regulation of peptide transport
Process GO:0090276 Regulation of peptide hormone secretion
Process GO:0090277 Positive regulation of peptide hormone secretion
Process GO:0090335 Regulation of brown fat cell differentiation
Process GO:0090336 Positive regulation of brown fat cell differentiation
Process GO:0097746 Blood vessel diameter maintenance
Process GO:0099175 Regulation of postsynapse organization
Process GO:0099177 Regulation of trans-synaptic signaling
Process GO:0106027 Neuron projection organization
Process GO:0120035 Regulation of plasma membrane bounded cell projection organization
Process GO:0120036 Plasma membrane bounded cell projection organization
Process GO:1900076 Regulation of cellular response to insulin stimulus
Process GO:1900078 Positive regulation of cellular response to insulin stimulus
Process GO:1900180 Regulation of protein localization to nucleus
Process GO:1900182 Positive regulation of protein localization to nucleus
Process GO:1900271 Regulation of long-term synaptic potentiation
Process GO:1900273 Positive regulation of long-term synaptic potentiation
Process GO:1900407 Regulation of cellular response to oxidative stress
Process GO:1900542 Regulation of purine nucleotide metabolic process
Process GO:1900544 Positive regulation of purine nucleotide metabolic process
Process GO:1901652 Response to peptide
Process GO:1901653 Cellular response to peptide
Process GO:1901698 Response to nitrogen compound
Process GO:1901699 Cellular response to nitrogen compound
Process GO:1901700 Response to oxygen-containing compound
Process GO:1901701 Cellular response to oxygen-containing compound
Process GO:1902175 Regulation of oxidative stress-induced intrinsic apoptotic signaling pathway
Process GO:1902176 Negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway
Process GO:1902531 Regulation of intracellular signal transduction
Process GO:1902532 Negative regulation of intracellular signal transduction
Process GO:1902533 Positive regulation of intracellular signal transduction
Process GO:1902882 Regulation of response to oxidative stress
Process GO:1902950 Regulation of dendritic spine maintenance
Process GO:1902952 Positive regulation of dendritic spine maintenance
Process GO:1903076 Regulation of protein localization to plasma membrane
Process GO:1903201 Regulation of oxidative stress-induced cell death
Process GO:1903202 Negative regulation of oxidative stress-induced cell death
Process GO:1903426 Regulation of reactive oxygen species biosynthetic process
Process GO:1903427 Negative regulation of reactive oxygen species biosynthetic process
Process GO:1903506 Regulation of nucleic acid-templated transcription
Process GO:1903530 Regulation of secretion by cell
Process GO:1903531 Negative regulation of secretion by cell
Process GO:1903532 Positive regulation of secretion by cell
Process GO:1903576 Response to L-arginine
Process GO:1903578 Regulation of ATP metabolic process
Process GO:1903580 Positive regulation of ATP metabolic process
Process GO:1903828 Negative regulation of protein localization
Process GO:1903829 Positive regulation of protein localization
Process GO:1904375 Regulation of protein localization to cell periphery
Process GO:1904950 Negative regulation of establishment of protein localization
Process GO:1904951 Positive regulation of establishment of protein localization
Process GO:1905475 Regulation of protein localization to membrane
Process GO:1990535 Neuron projection maintenance
Process GO:2000112 Regulation of cellular macromolecule biosynthetic process
Process GO:2000145 Regulation of cell motility
Process GO:2000147 Positive regulation of cell motility
Process GO:2000252 Negative regulation of feeding behavior
Process GO:2000377 Regulation of reactive oxygen species metabolic process
Process GO:2000378 Negative regulation of reactive oxygen species metabolic process
Process GO:2001141 Regulation of RNA biosynthetic process
Process GO:2001233 Regulation of apoptotic signaling pathway
Process GO:2001234 Negative regulation of apoptotic signaling pathway
Process GO:2001242 Regulation of intrinsic apoptotic signaling pathway
Process GO:2001243 Negative regulation of intrinsic apoptotic signaling pathway
Component GO:0000139 Golgi membrane
Component GO:0005576 Extracellular region
Component GO:0005615 Extracellular space
Component GO:0005622 Intracellular anatomical structure
Component GO:0005737 Cytoplasm
Component GO:0005768 Endosome
Component GO:0005783 Endoplasmic reticulum
Component GO:0005788 Endoplasmic reticulum lumen
Component GO:0005793 Endoplasmic reticulum-Golgi intermediate compartment
Component GO:0005794 Golgi apparatus
Component GO:0005796 Golgi lumen
Component GO:0012505 Endomembrane system
Component GO:0016020 Membrane
Component GO:0030133 Transport vesicle
Component GO:0030141 Secretory granule
Component GO:0031090 Organelle membrane
Component GO:0031410 Cytoplasmic vesicle
Component GO:0031904 Endosome lumen
Component GO:0031974 Membrane-enclosed lumen
Component GO:0031982 Vesicle
Component GO:0031983 Vesicle lumen
Component GO:0033116 Endoplasmic reticulum-Golgi intermediate compartment membrane
Component GO:0034774 Secretory granule lumen
Component GO:0043226 Organelle
Component GO:0043227 Membrane-bounded organelle
Component GO:0043229 Intracellular organelle
Component GO:0043231 Intracellular membrane-bounded organelle
Component GO:0043233 Organelle lumen
Component GO:0060205 Cytoplasmic vesicle lumen
Component GO:0070013 Intracellular organelle lumen
Component GO:0097708 Intracellular vesicle
Component GO:0098588 Bounding membrane of organelle
Component GO:0099503 Secretory vesicle
Component GO:0110165 Cellular anatomical entity
Function GO:0002020 Protease binding
Function GO:0005102 Signaling receptor binding
Function GO:0005158 Insulin receptor binding
Function GO:0005159 Insulin-like growth factor receptor binding
Function GO:0005179 Hormone activity
Function GO:0005488 Binding
Function GO:0005515 Protein binding
Function GO:0019899 Enzyme binding
Function GO:0030545 Signaling receptor regulator activity
Function GO:0030546 Signaling receptor activator activity
Function GO:0042802 Identical protein binding
Function GO:0044877 Protein-containing complex binding
Function GO:0048018 Receptor ligand activity
Function GO:0098772 Molecular function regulator activity

Pathway annotation


Category Term ID Term description
RCTM HSA-1257604 PIP3 activates AKT signaling
RCTM HSA-1266738 Developmental Biology
RCTM HSA-1430728 Metabolism
RCTM HSA-162582 Signal Transduction
RCTM HSA-163685 Integration of energy metabolism
RCTM HSA-186712 Regulation of beta-cell development
RCTM HSA-199418 Negative regulation of the PI3K/AKT network
RCTM HSA-199977 ER to Golgi Anterograde Transport
RCTM HSA-199991 Membrane Trafficking
RCTM HSA-210745 Regulation of gene expression in beta cells
RCTM HSA-212436 Generic Transcription Pathway
RCTM HSA-264876 Insulin processing
RCTM HSA-2980736 Peptide hormone metabolism
RCTM HSA-392499 Metabolism of proteins
RCTM HSA-422085 Synthesis, secretion, and deacylation of Ghrelin
RCTM HSA-422356 Regulation of insulin secretion
RCTM HSA-446203 Asparagine N-linked glycosylation
RCTM HSA-5653656 Vesicle-mediated transport
RCTM HSA-597592 Post-translational protein modification
RCTM HSA-6807878 COPI-mediated anterograde transport
RCTM HSA-6811558 PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
RCTM HSA-73857 RNA Polymerase II Transcription
RCTM HSA-74160 Gene expression (Transcription)
RCTM HSA-74713 IRS activation
RCTM HSA-74749 Signal attenuation
RCTM HSA-74751 Insulin receptor signalling cascade
RCTM HSA-74752 Signaling by Insulin receptor
RCTM HSA-77387 Insulin receptor recycling
RCTM HSA-9006925 Intracellular signaling by second messengers
RCTM HSA-9006934 Signaling by Receptor Tyrosine Kinases
RCTM HSA-948021 Transport to the Golgi and subsequent modification
RCTM HSA-9614085 FOXO-mediated transcription
RCTM HSA-9615017 FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes
RCTM HSA-9634815 Transcriptional Regulation by NPAS4
RCTM HSA-9768919 NPAS4 regulates expression of target genes
RCTM HSA-977225 Amyloid fiber formation
WikiPathways WP15 Selenium micronutrient network
WikiPathways WP1533 Vitamin B12 metabolism
WikiPathways WP176 Folate metabolism
WikiPathways WP1946 Cori cycle
WikiPathways WP1982 Sterol regulatory element-binding proteins (SREBP) signaling
WikiPathways WP2059 Alzheimers disease and miRNA effects
WikiPathways WP2324 AGE/RAGE pathway
WikiPathways WP236 Adipogenesis
WikiPathways WP2406 Cardiac progenitor differentiation
WikiPathways WP2509 Nanoparticle triggered autophagic cell death
WikiPathways WP2848 Pluripotent stem cell differentiation pathway
WikiPathways WP3915 Angiopoietin-like protein 8 regulatory pathway
WikiPathways WP3932 Focal adhesion: PI3K-Akt-mTOR-signaling pathway
WikiPathways WP3935 Leptin-insulin signaling overlap
WikiPathways WP3998 Prader-Willi and Angelman syndrome
WikiPathways WP4149 White fat cell differentiation
WikiPathways WP4172 PI3K-Akt signaling pathway
WikiPathways WP4396 Nonalcoholic fatty liver disease
WikiPathways WP4970 Galanin receptor pathway
WikiPathways WP5066 FOXA2 pathway
WikiPathways WP5087 Malignant pleural mesothelioma
WikiPathways WP5101 Congenital generalized lipodystrophy
WikiPathways WP5102 Familial partial lipodystrophy
WikiPathways WP5103 Progeria-associated lipodystrophy
WikiPathways WP5124 Alzheimers disease
WikiPathways WP5181 Roles of ceramides in development of insulin resistance
WikiPathways WP661 Glucose homeostasis
KEGG hsa04010 MAPK signaling pathway
KEGG hsa04014 Ras signaling pathway
KEGG hsa04015 Rap1 signaling pathway
KEGG hsa04022 cGMP-PKG signaling pathway
KEGG hsa04066 HIF-1 signaling pathway
KEGG hsa04068 FoxO signaling pathway
KEGG hsa04072 Phospholipase D signaling pathway
KEGG hsa04114 Oocyte meiosis
KEGG hsa04140 Autophagy - animal
KEGG hsa04150 mTOR signaling pathway
KEGG hsa04151 PI3K-Akt signaling pathway
KEGG hsa04152 AMPK signaling pathway
KEGG hsa04211 Longevity regulating pathway
KEGG hsa04213 Longevity regulating pathway - multiple species
KEGG hsa04810 Regulation of actin cytoskeleton
KEGG hsa04910 Insulin signaling pathway
KEGG hsa04911 Insulin secretion
KEGG hsa04913 Ovarian steroidogenesis
KEGG hsa04914 Progesterone-mediated oocyte maturation
KEGG hsa04917 Prolactin signaling pathway
KEGG hsa04923 Regulation of lipolysis in adipocytes
KEGG hsa04930 Type II diabetes mellitus
KEGG hsa04931 Insulin resistance
KEGG hsa04932 Non-alcoholic fatty liver disease
KEGG hsa04940 Type I diabetes mellitus
KEGG hsa04950 Maturity onset diabetes of the young
KEGG hsa04960 Aldosterone-regulated sodium reabsorption
KEGG hsa05010 Alzheimer disease
KEGG hsa05215 Prostate cancer
KEGG hsa05415 Diabetic cardiomyopathy

Expression profile of INS in omics data



ID GSE120596
Title Variability in the Analgesic Response to Ibuprofen Following Third Molar Extraction is Associated with Differences in Activation of the Cyclooxygenase Pathway
Organism Homo sapiens
GSM Sample info Characteristics Value
GSM3405450 1001_baseline cell type: peripheral blood mononuclear cell subject: 1001 gender: Female timepoint: baseline library barcode: ATTACTCG-TATAGCCT drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405451 1001_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1001 gender: Female timepoint: post-surgery 1 library barcode: TCCGGAGA-TATAGCCT drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405452 1002_baseline cell type: peripheral blood mononuclear cell subject: 1002 gender: Female timepoint: baseline library barcode: CGCTCATT-TATAGCCT drug treatment: Placebo response group: Placebo 0.0
GSM3405453 1002_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1002 gender: Female timepoint: post-surgery 1 library barcode: GAGATTCC-TATAGCCT drug treatment: Placebo response group: Placebo 0.0
GSM3405454 1003_baseline cell type: peripheral blood mononuclear cell subject: 1003 gender: Male timepoint: baseline library barcode: ATTCAGAA-TATAGCCT drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405455 1003_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1003 gender: Male timepoint: post-surgery 1 library barcode: GAATTCGT-TATAGCCT drug treatment: ibuprofen sodium response group: Full responder 2.0
GSM3405456 1004_baseline cell type: peripheral blood mononuclear cell subject: 1004 gender: Male timepoint: baseline library barcode: CTGAAGCT-TATAGCCT drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405457 1004_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1004 gender: Male timepoint: post-surgery 1 library barcode: TAATGCGC-TATAGCCT drug treatment: ibuprofen sodium response group: Partial responder
GSM3405458 1005_baseline cell type: peripheral blood mononuclear cell subject: 1005 gender: Male timepoint: baseline library barcode: CGGCTATG-TATAGCCT drug treatment: Placebo response group: Placebo 0.0
GSM3405459 1005_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1005 gender: Male timepoint: post-surgery 1 library barcode: TCCGCGAA-TATAGCCT drug treatment: Placebo response group: Placebo
GSM3405460 1006_baseline cell type: peripheral blood mononuclear cell subject: 1006 gender: Male timepoint: baseline library barcode: TCTCGCGC-TATAGCCT drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405461 1006_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1006 gender: Male timepoint: post-surgery 1 library barcode: AGCGATAG-TATAGCCT drug treatment: ibuprofen sodium response group: Partial responder 2.0
GSM3405462 1007_baseline cell type: peripheral blood mononuclear cell subject: 1007 gender: Male timepoint: baseline library barcode: ATTACTCG-ATAGAGGC drug treatment: ibuprofen sodium response group: Full responder
GSM3405463 1007_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1007 gender: Male timepoint: post-surgery 1 library barcode: TCCGGAGA-ATAGAGGC drug treatment: ibuprofen sodium response group: Full responder
GSM3405464 1008_baseline cell type: peripheral blood mononuclear cell subject: 1008 gender: Male timepoint: baseline library barcode: CGCTCATT-ATAGAGGC drug treatment: Placebo response group: Placebo
GSM3405465 1008_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1008 gender: Male timepoint: post-surgery 1 library barcode: GAGATTCC-ATAGAGGC drug treatment: Placebo response group: Placebo
GSM3405466 1008_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1008 gender: Male timepoint: post-surgery 2 library barcode: ATTCAGAA-ATAGAGGC drug treatment: Placebo response group: Placebo
GSM3405467 1011_baseline cell type: peripheral blood mononuclear cell subject: 1011 gender: Female timepoint: baseline library barcode: GAATTCGT-ATAGAGGC drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405468 1011_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1011 gender: Female timepoint: post-surgery 1 library barcode: CTGAAGCT-ATAGAGGC drug treatment: ibuprofen sodium response group: Full responder
GSM3405469 1011_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1011 gender: Female timepoint: post-surgery 2 library barcode: TAATGCGC-ATAGAGGC drug treatment: ibuprofen sodium response group: Full responder
GSM3405470 1012_baseline cell type: peripheral blood mononuclear cell subject: 1012 gender: Female timepoint: baseline library barcode: CGGCTATG-ATAGAGGC drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405471 1012_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1012 gender: Female timepoint: post-surgery 1 library barcode: TCCGCGAA-ATAGAGGC drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405472 1012_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1012 gender: Female timepoint: post-surgery 2 library barcode: TCTCGCGC-ATAGAGGC drug treatment: ibuprofen sodium response group: Partial responder
GSM3405473 1014_baseline cell type: peripheral blood mononuclear cell subject: 1014 gender: Male timepoint: baseline library barcode: AGCGATAG-ATAGAGGC drug treatment: Placebo response group: Placebo 0.0
GSM3405474 1014_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1014 gender: Male timepoint: post-surgery 1 library barcode: ATTACTCG-CCTATCCT drug treatment: Placebo response group: Placebo 0.0
GSM3405475 1014_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1014 gender: Male timepoint: post-surgery 2 library barcode: TCCGGAGA-CCTATCCT drug treatment: Placebo response group: Placebo 0.0
GSM3405476 1015_baseline cell type: peripheral blood mononuclear cell subject: 1015 gender: Male timepoint: baseline library barcode: CGCTCATT-CCTATCCT drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405477 1015_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1015 gender: Male timepoint: post-surgery 1 library barcode: GAGATTCC-CCTATCCT drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405478 1015_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1015 gender: Male timepoint: post-surgery 2 library barcode: ATTCAGAA-CCTATCCT drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405479 1016_baseline cell type: peripheral blood mononuclear cell subject: 1016 gender: Male timepoint: baseline library barcode: GAATTCGT-CCTATCCT drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405480 1016_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1016 gender: Male timepoint: post-surgery 1 library barcode: CTGAAGCT-CCTATCCT drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405481 1016_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1016 gender: Male timepoint: post-surgery 2 library barcode: TAATGCGC-CCTATCCT drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405482 1017_baseline cell type: peripheral blood mononuclear cell subject: 1017 gender: Male timepoint: baseline library barcode: CGGCTATG-CCTATCCT drug treatment: Placebo response group: Placebo 0.0
GSM3405483 1017_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1017 gender: Male timepoint: post-surgery 1 library barcode: TCCGCGAA-CCTATCCT drug treatment: Placebo response group: Placebo 0.0
GSM3405484 1017_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1017 gender: Male timepoint: post-surgery 2 library barcode: TCTCGCGC-CCTATCCT drug treatment: Placebo response group: Placebo 0.0
GSM3405485 1018_baseline cell type: peripheral blood mononuclear cell subject: 1018 gender: Female timepoint: baseline library barcode: AGCGATAG-CCTATCCT drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405486 1018_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1018 gender: Female timepoint: post-surgery 1 library barcode: ATTACTCG-GGCTCTGA drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405487 1018_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1018 gender: Female timepoint: post-surgery 2 library barcode: TCCGGAGA-GGCTCTGA drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405488 1019_baseline cell type: peripheral blood mononuclear cell subject: 1019 gender: Male timepoint: baseline library barcode: CGCTCATT-GGCTCTGA drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405489 1019_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1019 gender: Male timepoint: post-surgery 1 library barcode: GAGATTCC-GGCTCTGA drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405490 1019_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1019 gender: Male timepoint: post-surgery 2 library barcode: ATTCAGAA-GGCTCTGA drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405491 1020_baseline cell type: peripheral blood mononuclear cell subject: 1020 gender: Female timepoint: baseline library barcode: GAATTCGT-GGCTCTGA drug treatment: Placebo response group: Placebo
GSM3405492 1020_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1020 gender: Female timepoint: post-surgery 1 library barcode: CTGAAGCT-GGCTCTGA drug treatment: Placebo response group: Placebo 0.0
GSM3405493 1020_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1020 gender: Female timepoint: post-surgery 2 library barcode: TAATGCGC-GGCTCTGA drug treatment: Placebo response group: Placebo 0.0
GSM3405494 1021_baseline cell type: peripheral blood mononuclear cell subject: 1021 gender: Female timepoint: baseline library barcode: CGGCTATG-GGCTCTGA drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405495 1021_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1021 gender: Female timepoint: post-surgery 1 library barcode: TCCGCGAA-GGCTCTGA drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405496 1021_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1021 gender: Female timepoint: post-surgery 2 library barcode: TCTCGCGC-GGCTCTGA drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405497 1022_baseline cell type: peripheral blood mononuclear cell subject: 1022 gender: Male timepoint: baseline library barcode: AGCGATAG-GGCTCTGA drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405498 1022_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1022 gender: Male timepoint: post-surgery 1 library barcode: ATTACTCG-AGGCGAAG drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405499 1022_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1022 gender: Male timepoint: post-surgery 2 library barcode: TCCGGAGA-AGGCGAAG drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405500 1023_baseline cell type: peripheral blood mononuclear cell subject: 1023 gender: Male timepoint: baseline library barcode: CGCTCATT-AGGCGAAG drug treatment: Placebo response group: Placebo 0.0
GSM3405501 1023_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1023 gender: Male timepoint: post-surgery 1 library barcode: GAGATTCC-AGGCGAAG drug treatment: Placebo response group: Placebo 0.0
GSM3405502 1023_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1023 gender: Male timepoint: post-surgery 2 library barcode: ATTCAGAA-AGGCGAAG drug treatment: Placebo response group: Placebo 0.0
GSM3405503 1024_baseline cell type: peripheral blood mononuclear cell subject: 1024 gender: Female timepoint: baseline library barcode: GAATTCGT-AGGCGAAG drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405504 1024_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1024 gender: Female timepoint: post-surgery 1 library barcode: CTGAAGCT-AGGCGAAG drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405505 1024_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1024 gender: Female timepoint: post-surgery 2 library barcode: TAATGCGC-AGGCGAAG drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405506 1026_baseline cell type: peripheral blood mononuclear cell subject: 1026 gender: Female timepoint: baseline library barcode: CGGCTATG-AGGCGAAG drug treatment: Placebo response group: Placebo 0.0
GSM3405507 1026_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1026 gender: Female timepoint: post-surgery 1 library barcode: TCCGCGAA-AGGCGAAG drug treatment: Placebo response group: Placebo 0.0
GSM3405508 1026_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1026 gender: Female timepoint: post-surgery 2 library barcode: TCTCGCGC-AGGCGAAG drug treatment: Placebo response group: Placebo 0.0
GSM3405509 1027_baseline cell type: peripheral blood mononuclear cell subject: 1027 gender: Female timepoint: baseline library barcode: AGCGATAG-AGGCGAAG drug treatment: Placebo response group: Placebo 0.0
GSM3405510 1027_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1027 gender: Female timepoint: post-surgery 1 library barcode: ATTACTCG-TAATCTTA drug treatment: Placebo response group: Placebo 0.0
GSM3405511 1027_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1027 gender: Female timepoint: post-surgery 2 library barcode: TCCGGAGA-TAATCTTA drug treatment: Placebo response group: Placebo 0.0
GSM3405512 1028_baseline cell type: peripheral blood mononuclear cell subject: 1028 gender: Male timepoint: baseline library barcode: CGCTCATT-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405513 1028_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1028 gender: Male timepoint: post-surgery 1 library barcode: GAGATTCC-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405514 1028_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1028 gender: Male timepoint: post-surgery 2 library barcode: ATTCAGAA-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405515 1029_baseline cell type: peripheral blood mononuclear cell subject: 1029 gender: Male timepoint: baseline library barcode: GAATTCGT-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405516 1029_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1029 gender: Male timepoint: post-surgery 1 library barcode: CTGAAGCT-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405517 1029_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1029 gender: Male timepoint: post-surgery 2 library barcode: TAATGCGC-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405518 1030_baseline cell type: peripheral blood mononuclear cell subject: 1030 gender: Female timepoint: baseline library barcode: CGGCTATG-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405519 1030_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1030 gender: Female timepoint: post-surgery 1 library barcode: TCCGCGAA-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405520 1030_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1030 gender: Female timepoint: post-surgery 2 library barcode: TCTCGCGC-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder 0.0
GSM3405521 1032_baseline cell type: peripheral blood mononuclear cell subject: 1032 gender: Female timepoint: baseline library barcode: AGCGATAG-TAATCTTA drug treatment: Placebo response group: Placebo 0.0
GSM3405522 1032_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1032 gender: Female timepoint: post-surgery 1 library barcode: ATTACTCG-CAGGACGT drug treatment: Placebo response group: Placebo 0.0
GSM3405523 1032_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1032 gender: Female timepoint: post-surgery 2 library barcode: TCCGGAGA-CAGGACGT drug treatment: Placebo response group: Placebo 0.0
GSM3405524 1033_baseline cell type: peripheral blood mononuclear cell subject: 1033 gender: Male timepoint: baseline library barcode: CGCTCATT-CAGGACGT drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405525 1033_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1033 gender: Male timepoint: post-surgery 1 library barcode: GAGATTCC-CAGGACGT drug treatment: ibuprofen sodium response group: Full responder 0.0
GSM3405526 1033_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1033 gender: Male timepoint: post-surgery 2 library barcode: ATTCAGAA-CAGGACGT drug treatment: ibuprofen sodium response group: Full responder 0.0

ID GSE12860
Title Antirheumatic Drug Response in Human Chondrocytes: Potential Molecular Targets to Stimulate Cartilage Regeneration
Organism Homo sapiens
GSM Sample info Characteristics Value
GSM322609 RASF stimulated chondrocytes rep 1 GSM253283 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium 4.962893539
GSM322610 RASF stimulated chondrocytes rep 2 GSM253284 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium 4.91668414
GSM322611 NDSF stimulated chondrocytes rep 1 GSM253285 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of NDSF cultured in the same medium 4.934846777
GSM322612 NDSF stimulated chondrocytes rep 2 GSM253286 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of NDSF cultured in the same medium 4.917944533
GSM322613 Chondrocytes stimulated with diclofenac treated RASF rep 1 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with diclofenac for 48h 5.345127296
GSM322614 Chondrocytes stimulated with diclofenac treated RASF rep 2 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with diclofenac for 48h 4.899326392
GSM322615 Chondrocytes stimulated with prioxicam treated RASF rep 1 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with piroxicam for 48h 4.816307634
GSM322616 Chondrocytes stimulated with prioxicam treated RASF rep 2 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with piroxicam for 48h 4.825853641
GSM322617 Chondrocytes stimulated with chloroquine phosphate (resochin) treated RASF rep 1 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with chloroquine phosphate (resochin) for 48h 4.986352269
GSM322618 Chondrocytes stimulated with chloroquine phosphate (resochin) treated RASF rep 2 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with chloroquine phosphate (resochin) for 48h 4.920423437
GSM322619 Chondrocytes stimulated with sodium aurothiomalate (tauredon) treated RASF rep 1 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with sodium aurothiomalate (tauredon) for 48h 4.883317011
GSM322620 Chondrocytes stimulated with sodium aurothiomalate (tauredon) treated RASF rep 2 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with sodium aurothiomalate (tauredon) for 48h 4.941998049
GSM322621 Chondrocytes stimulated with azathioprine (imurek) treated RASF rep 1 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with azathioprine (imurek) for 48h 4.809437232
GSM322622 Chondrocytes stimulated with azathioprine (imurek) treated RASF rep 2 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with azathioprine (imurek) for 48h 4.813968591
GSM322623 Chondrocytes stimulated with methotrexate treated RASF rep 1 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with methotrexate for 48h 4.894011372
GSM322624 Chondrocytes stimulated with methotrexate treated RASF rep 2 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with methotrexate for 48h 4.888900341
GSM322625 Chondrocytes stimulated with prednisolone (solu-decortin) treated RASF rep 1 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with prednisolone (solu-decortin) for 48h 4.936558323
GSM322626 Chondrocytes stimulated with prednisolone (solu-decortin) treated RASF rep 2 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with prednisolone (solu-decortin) for 48h 4.974519725
GSM322627 Chondrocytes stimulated with methylprednisolone (urbason) treated RASF rep 1 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with methylprednisolone (urbason) for 48h 4.925718219
GSM322628 Chondrocytes stimulated with methylprednisolone (urbason) treated RASF rep 2 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with methylprednisolone (urbason) for 48h 4.890018811

ID GSE150408
Title Identification of key genes potentially related to intervertebral disc degeneration by microarray analysis
Organism Homo sapiens
GSM Sample info Characteristics Value
GSM4548691 volunteer-9 tissue: whole blood diagnosis: healthy control treatment: n/a 1.486348676
GSM4548692 volunteer-10 tissue: whole blood diagnosis: healthy control treatment: n/a 3.87853768
GSM4548693 volunteer-11 tissue: whole blood diagnosis: healthy control treatment: n/a 1.645021644
GSM4548694 volunteer-12 tissue: whole blood diagnosis: healthy control treatment: n/a 1.550515218
GSM4548695 volunteer-13 tissue: whole blood diagnosis: healthy control treatment: n/a 2.872411898
GSM4548696 volunteer-14 tissue: whole blood diagnosis: healthy control treatment: n/a 1.675356038
GSM4548697 volunteer-15 tissue: whole blood diagnosis: healthy control treatment: n/a 3.341443909
GSM4548698 volunteer-16 tissue: whole blood diagnosis: healthy control treatment: n/a 3.466983686
GSM4548699 volunteer-17 tissue: whole blood diagnosis: healthy control treatment: n/a 2.702125124
GSM4548700 volunteer-18 tissue: whole blood diagnosis: healthy control treatment: n/a 1.849613998
GSM4548701 volunteer-19 tissue: whole blood diagnosis: healthy control treatment: n/a 2.724058149
GSM4548702 volunteer-20 tissue: whole blood diagnosis: healthy control treatment: n/a 2.7475554
GSM4548703 volunteer-21 tissue: whole blood diagnosis: healthy control treatment: n/a 3.407127795
GSM4548704 volunteer-22 tissue: whole blood diagnosis: healthy control treatment: n/a 1.574619006
GSM4548705 volunteer-23 tissue: whole blood diagnosis: healthy control treatment: n/a 1.651396572
GSM4548706 volunteer-24 tissue: whole blood diagnosis: healthy control treatment: n/a 2.910022436
GSM4548707 volunteer-25 tissue: whole blood diagnosis: healthy control treatment: n/a 1.716288792
GSM4548708 patient-9 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 4.120394445
GSM4548709 patient-10 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 2.706321935
GSM4548710 patient-11 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 3.301503519
GSM4548711 patient-12 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 3.858349554
GSM4548712 patient-13 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 1.62476307
GSM4548713 patient-14 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 2.960601815
GSM4548714 patient-15 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 3.861292961
GSM4548715 patient-16 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 3.574851821
GSM4548716 patient-17 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 3.143497974
GSM4548717 patient-18 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 3.242786781
GSM4548718 patient-19 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 1.62821451
GSM4548719 patient-20 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 3.876067806
GSM4548720 patient-21 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 3.25956968
GSM4548721 patient-22 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 3.057707988
GSM4548722 patient-23 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 2.73217319
GSM4548723 patient-24 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 2.760827669
GSM4548724 patient-25 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 2.685452307
GSM4548725 treatment-1 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 3.418480827
GSM4548726 treatment-2 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 2.719230894
GSM4548727 treatment-3 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 1.618817641
GSM4548728 treatment-4 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 2.434321025
GSM4548729 treatment-5 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 3.672497857
GSM4548730 treatment-6 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 1.84882201
GSM4548731 treatment-7 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 2.054767786
GSM4548732 treatment-8 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 2.400890698
GSM4548733 treatment-9 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 1.933075556
GSM4548734 treatment-10 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 3.323153167
GSM4548735 treatment-11 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 2.235956447
GSM4548736 treatment-12 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 2.241046916
GSM4548737 treatment-13 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 1.67687654
GSM4548738 treatment-14 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 1.862156245
GSM4548739 treatment-15 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 2.866277395
GSM4548740 treatment-16 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 2.991134288
GSM4548741 treatment-17 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 3.233413987
GSM4548742 treatment-18 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 1.603696586
GSM4548743 treatment-19 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 3.616529982
GSM4548744 treatment-20 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 2.721984265
GSM4548745 treatment-21 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 2.782616038
GSM4548746 treatment-22 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 3.308648702
GSM4548747 treatment-23 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 1.656772771
GSM4548748 treatment-24 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 3.150950644
GSM4548749 treatment-25 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 2.897857042

ID GSE179004
Title Expression data from glioblastoma surgical specimens
Organism Homo sapiens
GSM Sample info Characteristics Value
GSM5403447 glioblastoma tissue 1 in TIVA group tissue: glioblastoma 1.985642852
GSM5403448 glioblastoma tissue 2 in TIVA group tissue: glioblastoma 2.784275398
GSM5403449 glioblastoma tissue 3 in TIVA group tissue: glioblastoma 2.615860548
GSM5403450 glioblastoma tissue 1 in INHA group tissue: glioblastoma 2.19384735
GSM5403451 glioblastoma tissue 2 in INHA group tissue: glioblastoma 2.377079197
GSM5403452 glioblastoma tissue 3 in INHA group tissue: glioblastoma 3.146812607

ID GSE212044
Title Reversibility of etomidate-induced contractile arrest through activation of myocardial autophagy
Organism Homo sapiens
GSM Sample info Characteristics Value
GSM6508421 IPSC-CM cells, DSMO 1 cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: DSMO time: Day 30 0.0
GSM6508422 IPSC-CM cells, DSMO 2 cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: DSMO time: Day 30 0.0
GSM6508423 IPSC-CM cells, DSMO 3 cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: DSMO time: Day 30 0.0
GSM6508424 IPSC-CM cells, Etomidate 1 cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: Etomidate time: Day 30 0.0
GSM6508425 IPSC-CM cells, Etomidate 2 cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: Etomidate time: Day 30 0.0
GSM6508426 IPSC-CM cells, Etomidate 3 cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: Etomidate time: Day 30 1.0
GSM6508427 IPSC-CM cells, Propofol 1 cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: Propofol time: Day 30 0.0
GSM6508428 IPSC-CM cells, Propofol 2 cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: Propofol time: Day 30 0.0
GSM6508429 IPSC-CM cells, Propofol 3 cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: Propofol time: Day 30 0.0

ID GSE255952
Title Transcriptome data of B cells and T helper cells from patients with multiple sclerosis receiving methylprednisolone for the treatment of an acute relapse
Organism Homo sapiens
GSM Sample info Characteristics Value
GSM8083291 patient C1P1, before first course of MP, T cells tissue: peripheral blood patient id: C1P1 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: non-responder percentage in pbmc: 34.9 cells per ml: 2982000 purity (%): 98.1 rna integrity number: 7.8 age (years): 60 Sex: female body weight (in kg): 75.4 body size (in cm): 168 body mass index: 26.7 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 11 number of relapses in the past 2 years: 0 duration since last relapse (months): 133 edss score: 3.5 disease-modifying therapy: teriflunomide number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: hair loss 3.65612
GSM8083292 patient C1P1, after first course of MP, T cells tissue: peripheral blood patient id: C1P1 mp course: first time point: after cell population: CD4+ T cells clinical evaluation: non-responder percentage in pbmc: 25.9 cells per ml: 304500 purity (%): 95.3 rna integrity number: 8.7 age (years): 60 Sex: female body weight (in kg): 75.4 body size (in cm): 168 body mass index: 26.7 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 11 number of relapses in the past 2 years: 0 duration since last relapse (months): 133 edss score: NA disease-modifying therapy: teriflunomide number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: worse fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: hair loss 3.91083
GSM8083293 patient C1P1, before second course of MP, T cells tissue: peripheral blood patient id: C1P1 mp course: second time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 27.8 cells per ml: 1254750 purity (%): 96.7 rna integrity number: 8.3 age (years): 60 Sex: female body weight (in kg): 75.4 body size (in cm): 168 body mass index: 26.7 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 11 number of relapses in the past 2 years: 0 duration since last relapse (months): 134 edss score: 3.5 disease-modifying therapy: teriflunomide number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 6000 days from first to last mp application: 2 side effects to mp: headache, diarrhea 3.32207
GSM8083294 patient C1P1, after second course of MP, T cells tissue: peripheral blood patient id: C1P1 mp course: second time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 6.6 cells per ml: 231000 purity (%): 93.7 rna integrity number: 9.4 age (years): 60 Sex: female body weight (in kg): 75.4 body size (in cm): 168 body mass index: 26.7 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 11 number of relapses in the past 2 years: 0 duration since last relapse (months): 134 edss score: NA disease-modifying therapy: teriflunomide number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: worse fs: sensory: better fs: visual: unchanged total dose of mp in mg: 6000 days from first to last mp application: 2 side effects to mp: headache, diarrhea 3.3271
GSM8083295 patient C1P2, before first course of MP, B cells tissue: peripheral blood patient id: C1P2 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 4.7 cells per ml: 236250 purity (%): 91.9 rna integrity number: 9.0 age (years): 38 Sex: male body weight (in kg): 67 body size (in cm): 183 body mass index: 20.0 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 17 number of relapses in the past 2 years: 0 duration since last relapse (months): 206 edss score: 3.0 disease-modifying therapy: teriflunomide number of other medications taken: 0 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: yes fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 6 side effects to mp: none 2.87918
GSM8083296 patient C1P2, after first course of MP, B cells tissue: peripheral blood patient id: C1P2 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 3.7 cells per ml: 283500 purity (%): 91.0 rna integrity number: 9.1 age (years): 38 Sex: male body weight (in kg): 67 body size (in cm): 183 body mass index: 20.0 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 17 number of relapses in the past 2 years: 0 duration since last relapse (months): 206 edss score: 3.0 disease-modifying therapy: teriflunomide number of other medications taken: 0 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: better fs: cerebral: unchanged fs: pyramidal: better fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 6 side effects to mp: none 3.20774
GSM8083297 patient C1P2, before first course of MP, T cells tissue: peripheral blood patient id: C1P2 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 28.7 cells per ml: 693000 purity (%): 96.0 rna integrity number: 8.3 age (years): 38 Sex: male body weight (in kg): 67 body size (in cm): 183 body mass index: 20.0 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 17 number of relapses in the past 2 years: 0 duration since last relapse (months): 206 edss score: 3.0 disease-modifying therapy: teriflunomide number of other medications taken: 0 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: yes fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 6 side effects to mp: none 3.54965
GSM8083298 patient C1P2, after first course of MP, T cells tissue: peripheral blood patient id: C1P2 mp course: first time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 11.5 cells per ml: 624750 purity (%): 96.0 rna integrity number: 8.3 age (years): 38 Sex: male body weight (in kg): 67 body size (in cm): 183 body mass index: 20.0 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 17 number of relapses in the past 2 years: 0 duration since last relapse (months): 206 edss score: 3.0 disease-modifying therapy: teriflunomide number of other medications taken: 0 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: better fs: cerebral: unchanged fs: pyramidal: better fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 6 side effects to mp: none 3.37181
GSM8083299 patient C1P3, before first course of MP, B cells tissue: peripheral blood patient id: C1P3 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 10.0 cells per ml: 498750 purity (%): 98.8 rna integrity number: 8.9 age (years): 34 Sex: female body weight (in kg): 63 body size (in cm): 168 body mass index: 22.3 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 8 number of relapses in the past 2 years: 1 duration since last relapse (months): 5 edss score: 2.5 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 1 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 3.32108
GSM8083300 patient C1P3, after first course of MP, B cells tissue: peripheral blood patient id: C1P3 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 6.7 cells per ml: 383250 purity (%): 97.9 rna integrity number: 9.4 age (years): 34 Sex: female body weight (in kg): 63 body size (in cm): 168 body mass index: 22.3 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 8 number of relapses in the past 2 years: 1 duration since last relapse (months): 5 edss score: 2.5 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 1 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 2.79569
GSM8083301 patient C1P3, before first course of MP, T cells tissue: peripheral blood patient id: C1P3 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 31.0 cells per ml: 1134000 purity (%): 94.7 rna integrity number: 8.1 age (years): 34 Sex: female body weight (in kg): 63 body size (in cm): 168 body mass index: 22.3 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 8 number of relapses in the past 2 years: 1 duration since last relapse (months): 5 edss score: 2.5 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 1 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 3.28044
GSM8083302 patient C1P3, after first course of MP, T cells tissue: peripheral blood patient id: C1P3 mp course: first time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 18.1 cells per ml: 640500 purity (%): 96.2 rna integrity number: 8.1 age (years): 34 Sex: female body weight (in kg): 63 body size (in cm): 168 body mass index: 22.3 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 8 number of relapses in the past 2 years: 1 duration since last relapse (months): 5 edss score: 2.5 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 1 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 3.54339
GSM8083303 patient C1P3, before second course of MP, T cells tissue: peripheral blood patient id: C1P3 mp course: second time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 30.3 cells per ml: 897750 purity (%): 97.0 rna integrity number: 8.5 age (years): 34 Sex: female body weight (in kg): 63 body size (in cm): 168 body mass index: 22.3 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 8 number of relapses in the past 2 years: 1 duration since last relapse (months): 5 edss score: 2.5 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 1 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 6000 days from first to last mp 3.28079
GSM8083304 patient C1P3, after second course of MP, T cells tissue: peripheral blood patient id: C1P3 mp course: second time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 27.7 cells per ml: 1433250 purity (%): 97.5 rna integrity number: 8.3 age (years): 34 Sex: female body weight (in kg): 63 body size (in cm): 168 body mass index: 22.3 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 8 number of relapses in the past 2 years: 1 duration since last relapse (months): 5 edss score: 2.5 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 1 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: unchanged total dose of mp in mg: 6000 days from first to last mp application: 5 side effects to mp: none 3.26189
GSM8083305 patient C1P4, before first course of MP, B cells tissue: peripheral blood patient id: C1P4 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 7.3 cells per ml: 378000 purity (%): 96.3 rna integrity number: 9.6 age (years): 53 Sex: female body weight (in kg): 58 body size (in cm): 159 body mass index: 22.9 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 3 number of relapses in the past 2 years: 0 duration since last relapse (months): 34 edss score: 3.0 disease-modifying therapy: glatiramer acetate number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 3.30188
GSM8083306 patient C1P4, after first course of MP, B cells tissue: peripheral blood patient id: C1P4 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 7.5 cells per ml: 939750 purity (%): 96.7 rna integrity number: 8.8 age (years): 53 Sex: female body weight (in kg): 58 body size (in cm): 159 body mass index: 22.9 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 3 number of relapses in the past 2 years: 0 duration since last relapse (months): 34 edss score: NA disease-modifying therapy: glatiramer acetate number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 3.25769
GSM8083307 patient C1P4, before first course of MP, T cells tissue: peripheral blood patient id: C1P4 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 38.1 cells per ml: 1522500 purity (%): 98.7 rna integrity number: NA age (years): 53 Sex: female body weight (in kg): 58 body size (in cm): 159 body mass index: 22.9 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 3 number of relapses in the past 2 years: 0 duration since last relapse (months): 34 edss score: 3.0 disease-modifying therapy: glatiramer acetate number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 3.37739
GSM8083308 patient C1P4, after first course of MP, T cells tissue: peripheral blood patient id: C1P4 mp course: first time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 15.9 cells per ml: 1617000 purity (%): 98.3 rna integrity number: 8.5 age (years): 53 Sex: female body weight (in kg): 58 body size (in cm): 159 body mass index: 22.9 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 3 number of relapses in the past 2 years: 0 duration since last relapse (months): 34 edss score: NA disease-modifying therapy: glatiramer acetate number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 3.1462
GSM8083309 patient C1P5, before first course of MP, T cells tissue: peripheral blood patient id: C1P5 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: non-responder percentage in pbmc: 31.6 cells per ml: 1344000 purity (%): 99.1 rna integrity number: 8.0 age (years): 42 Sex: male body weight (in kg): 57 body size (in cm): 180 body mass index: 17.6 current smoker: yes study center: Berlin course of disease: CIS/RRMS disease duration (years): 16 number of relapses in the past 2 years: 2 duration since last relapse (months): NA edss score: 7.5 disease-modifying therapy: ocrelizumab number of other medications taken: 6 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: no fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 5 side effects to mp: none 3.28517
GSM8083310 patient C1P5, after first course of MP, T cells tissue: peripheral blood patient id: C1P5 mp course: first time point: after cell population: CD4+ T cells clinical evaluation: non-responder percentage in pbmc: 21.9 cells per ml: 1165500 purity (%): 98.9 rna integrity number: 8.4 age (years): 42 Sex: male body weight (in kg): 57 body size (in cm): 180 body mass index: 17.6 current smoker: yes study center: Berlin course of disease: CIS/RRMS disease duration (years): 16 number of relapses in the past 2 years: 2 duration since last relapse (months): NA edss score: 7.5 disease-modifying therapy: ocrelizumab number of other medications taken: 6 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 5 side effects to mp: none 3.4015
GSM8083311 patient C1P5, before second course of MP, T cells tissue: peripheral blood patient id: C1P5 mp course: second time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 26.9 cells per ml: 1233750 purity (%): 97.8 rna integrity number: 8.5 age (years): 42 Sex: male body weight (in kg): 57 body size (in cm): 180 body mass index: 17.6 current smoker: yes study center: Berlin course of disease: CIS/RRMS disease duration (years): 16 number of relapses in the past 2 years: 2 duration since last relapse (months): NA edss score: 7.5 disease-modifying therapy: ocrelizumab number of other medications taken: 6 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: no fs: visual: no total dose of mp in mg: 4000 days from first to last mp application: 2 side effects to mp: cardiovascular problems 3.18074
GSM8083312 patient C1P5, after second course of MP, T cells tissue: peripheral blood patient id: C1P5 mp course: second time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 11.0 cells per ml: 514500 purity (%): 98.6 rna integrity number: 8.7 age (years): 42 Sex: male body weight (in kg): 57 body size (in cm): 180 body mass index: 17.6 current smoker: yes study center: Berlin course of disease: CIS/RRMS disease duration (years): 16 number of relapses in the past 2 years: 2 duration since last relapse (months): NA edss score: 7.5 disease-modifying therapy: ocrelizumab number of other medications taken: 6 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 4000 days from first to last mp application: 2 side effects to mp: cardiovascular problems 3.20518
GSM8083313 patient C2P1, before first course of MP, B cells tissue: peripheral blood patient id: C2P1 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 11.7 cells per ml: 2604000 purity (%): 96.7 rna integrity number: 8.5 age (years): 24 Sex: female body weight (in kg): 60 body size (in cm): 170 body mass index: 20.8 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 1 duration since last relapse (months): 6 edss score: 3.0 disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 2.93053
GSM8083314 patient C2P1, after first course of MP, B cells tissue: peripheral blood patient id: C2P1 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 8.8 cells per ml: 630000 purity (%): 97.4 rna integrity number: 8.4 age (years): 24 Sex: female body weight (in kg): 60 body size (in cm): 170 body mass index: 20.8 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 1 duration since last relapse (months): 6 edss score: NA disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 2.7008
GSM8083315 patient C2P1, before first course of MP, T cells tissue: peripheral blood patient id: C2P1 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 41.5 cells per ml: 2436000 purity (%): 94.6 rna integrity number: 8.0 age (years): 24 Sex: female body weight (in kg): 60 body size (in cm): 170 body mass index: 20.8 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 1 duration since last relapse (months): 6 edss score: 3.0 disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 3.02427
GSM8083316 patient C2P1, after first course of MP, T cells tissue: peripheral blood patient id: C2P1 mp course: first time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 6.2 cells per ml: 346500 purity (%): 86.5 rna integrity number: 8.0 age (years): 24 Sex: female body weight (in kg): 60 body size (in cm): 170 body mass index: 20.8 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 1 duration since last relapse (months): 6 edss score: NA disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 3.20011
GSM8083317 patient C2P2, before first course of MP, B cells tissue: peripheral blood patient id: C2P2 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 0.9 cells per ml: 467250 purity (%): 87.3 rna integrity number: 8.8 age (years): 41 Sex: female body weight (in kg): 71 body size (in cm): 170 body mass index: 24.6 current smoker: no study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 3 duration since last relapse (months): 3 edss score: NA disease-modifying therapy: glatiramer acetate number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 2.92831
GSM8083318 patient C2P2, after first course of MP, B cells tissue: peripheral blood patient id: C2P2 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 6.3 cells per ml: 199500 purity (%): 97.6 rna integrity number: 9.5 age (years): 41 Sex: female body weight (in kg): 71 body size (in cm): 170 body mass index: 24.6 current smoker: no study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 3 duration since last relapse (months): 3 edss score: 1.5 disease-modifying therapy: glatiramer acetate number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 2.99859
GSM8083319 patient C2P3, before first course of MP, B cells tissue: peripheral blood patient id: C2P3 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 12.2 cells per ml: 1170750 purity (%): 97.2 rna integrity number: 8.5 age (years): 20 Sex: female body weight (in kg): 55 body size (in cm): 165 body mass index: 20.2 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 6 number of relapses in the past 2 years: 0 duration since last relapse (months): NA edss score: 1.5 disease-modifying therapy: natalizumab number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 2.87451
GSM8083320 patient C2P3, after first course of MP, B cells tissue: peripheral blood patient id: C2P3 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 12.2 cells per ml: 1170750 purity (%): 97.2 rna integrity number: 8.5 age (years): 20 Sex: female body weight (in kg): 55 body size (in cm): 165 body mass index: 20.2 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 6 number of relapses in the past 2 years: 0 duration since last relapse (months): NA edss score: 1.5 disease-modifying therapy: natalizumab number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 3.21478
GSM8083321 patient C2P3, before first course of MP, T cells tissue: peripheral blood patient id: C2P3 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 20.2 cells per ml: 1711500 purity (%): 94.3 rna integrity number: 7.3 age (years): 20 Sex: female body weight (in kg): 55 body size (in cm): 165 body mass index: 20.2 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 6 number of relapses in the past 2 years: 0 duration since last relapse (months): NA edss score: 1.5 disease-modifying therapy: natalizumab number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 3.4185
GSM8083322 patient C2P3, after first course of MP, T cells tissue: peripheral blood patient id: C2P3 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 22.8 cells per ml: 992250 purity (%): 96.5 rna integrity number: 8.2 age (years): 20 Sex: female body weight (in kg): 55 body size (in cm): 165 body mass index: 20.2 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 6 number of relapses in the past 2 years: 0 duration since last relapse (months): NA edss score: 1.5 disease-modifying therapy: natalizumab number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 3.63211
GSM8083323 patient C2P4, before first course of MP, B cells tissue: peripheral blood patient id: C2P4 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: non-responder percentage in pbmc: 8.0 cells per ml: 1690500 purity (%): 96.3 rna integrity number: 9.0 age (years): 60 Sex: male body weight (in kg): 97 body size (in cm): 170 body mass index: 33.6 current smoker: no study center: Greifswald course of disease: CIS/RRMS disease duration (years): 7 number of relapses in the past 2 years: 1 duration since last relapse (months): 10 edss score: 2.0 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 8 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: yes fs: pyramidal: no fs: sensory: no fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 2.89414
GSM8083324 patient C2P4, after first course of MP, B cells tissue: peripheral blood patient id: C2P4 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: non-responder percentage in pbmc: 2.2 cells per ml: 273000 purity (%): 93.0 rna integrity number: 8.3 age (years): 60 Sex: male body weight (in kg): 97 body size (in cm): 170 body mass index: 33.6 current smoker: no study center: Greifswald course of disease: CIS/RRMS disease duration (years): 7 number of relapses in the past 2 years: 1 duration since last relapse (months): 10 edss score: 2.0 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 8 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 3.09453
GSM8083325 patient C2P5, before first course of MP, B cells tissue: peripheral blood patient id: C2P5 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 2.6 cells per ml: 136500 purity (%): 53.8 rna integrity number: 6.9 age (years): 59 Sex: female body weight (in kg): 60 body size (in cm): 172 body mass index: 20.3 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 4 number of relapses in the past 2 years: 1 duration since last relapse (months): 22 edss score: 3.0 disease-modifying therapy: none number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 3.18147
GSM8083326 patient C2P5, after first course of MP, B cells tissue: peripheral blood patient id: C2P5 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 6.8 cells per ml: 687750 purity (%): 98.1 rna integrity number: 8.2 age (years): 59 Sex: female body weight (in kg): 60 body size (in cm): 172 body mass index: 20.3 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 4 number of relapses in the past 2 years: 1 duration since last relapse (months): 22 edss score: 2.0 disease-modifying therapy: none number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 2.78047
GSM8083327 patient C2P6, before first course of MP, B cells tissue: peripheral blood patient id: C2P6 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: non-responder percentage in pbmc: 4.2 cells per ml: 546000 purity (%): 92.4 rna integrity number: 8.8 age (years): 39 Sex: female body weight (in kg): 54 body size (in cm): 164 body mass index: 20.1 current smoker: no study center: Greifswald course of disease: CIS/RRMS disease duration (years): 18 number of relapses in the past 2 years: 0 duration since last relapse (months): 47 edss score: 6.5 disease-modifying therapy: dimethyl fumarate number of other medications taken: 3 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: no fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 3.31407
GSM8083328 patient C2P6, after first course of MP, B cells tissue: peripheral blood patient id: C2P6 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: non-responder percentage in pbmc: 6.6 cells per ml: 714000 purity (%): 97.8 rna integrity number: 9.0 age (years): 39 Sex: female body weight (in kg): 54 body size (in cm): 164 body mass index: 20.1 current smoker: no study center: Greifswald course of disease: CIS/RRMS disease duration (years): 18 number of relapses in the past 2 years: 0 duration since last relapse (months): 47 edss score: NA disease-modifying therapy: dimethyl fumarate number of other medications taken: 3 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 2.70848
GSM8083329 patient C2P7, before first course of MP, B cells tissue: peripheral blood patient id: C2P7 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 2.7 cells per ml: 215250 purity (%): 95.6 rna integrity number: 7.8 age (years): 36 Sex: male body weight (in kg): 90 body size (in cm): NA body mass index: NA current smoker: NA study center: Greifswald course of disease: CIS/RRMS disease duration (years): 16 number of relapses in the past 2 years: 1 duration since last relapse (months): 21 edss score: 3.0 disease-modifying therapy: none number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: yes fs: cerebellar: no fs: cerebral: yes fs: pyramidal: no fs: sensory: no fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 2 side effects to mp: none 3.28455
GSM8083330 patient C2P7, after first course of MP, B cells tissue: peripheral blood patient id: C2P7 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 2.8 cells per ml: 162750 purity (%): 93.2 rna integrity number: 7.8 age (years): 36 Sex: male body weight (in kg): 90 body size (in cm): NA body mass index: NA current smoker: NA study center: Greifswald course of disease: CIS/RRMS disease duration (years): 16 number of relapses in the past 2 years: 1 duration since last relapse (months): 21 edss score: 3.0 disease-modifying therapy: none number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: better fs: pyramidal: unchanged fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 2 side effects to mp: none 2.539
GSM8083331 patient C2P8, before first course of MP, B cells tissue: peripheral blood patient id: C2P8 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: non-responder percentage in pbmc: 3.5 cells per ml: 220500 purity (%): 95.5 rna integrity number: 8.5 age (years): 23 Sex: female body weight (in kg): NA body size (in cm): NA body mass index: NA current smoker: NA study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 1 duration since last relapse (months): 10 edss score: 2.0 disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 2.93287
GSM8083332 patient C2P8, after first course of MP, B cells tissue: peripheral blood patient id: C2P8 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: non-responder percentage in pbmc: 11.0 cells per ml: 535500 purity (%): 97.3 rna integrity number: 7.5 age (years): 23 Sex: female body weight (in kg): NA body size (in cm): NA body mass index: NA current smoker: NA study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 1 duration since last relapse (months): 10 edss score: NA disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 2.82059
GSM8083333 patient C3P1, before second course of MP, T cells tissue: peripheral blood patient id: C3P1 mp course: second time point: before cell population: CD4+ T cells clinical evaluation: non-responder percentage in pbmc: 24.0 cells per ml: 225750 purity (%): 97.0 rna integrity number: 7.9 age (years): 36 Sex: female body weight (in kg): 63 body size (in cm): 175 body mass index: 20.6 current smoker: yes study center: Jena course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 2 duration since last relapse (months): NA edss score: 2.5 disease-modifying therapy: dimethyl fumarate number of other medications taken: 0 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: yes total dose of mp in mg: 10000 days from first to last mp application: 6 side effects to mp: none 3.68526
GSM8083334 patient C3P1, after second course of MP, T cells tissue: peripheral blood patient id: C3P1 mp course: second time point: after cell population: CD4+ T cells clinical evaluation: non-responder percentage in pbmc: 10.1 cells per ml: 315000 purity (%): 98.6 rna integrity number: 8.3 age (years): 36 Sex: female body weight (in kg): 63 body size (in cm): 175 body mass index: 20.6 current smoker: yes study center: Jena course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 2 duration since last relapse (months): NA edss score: 2.5 disease-modifying therapy: dimethyl fumarate number of other medications taken: 0 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: worse total dose of mp in mg: 10000 days from first to last mp application: 6 side effects to mp: none 3.34413
GSM8083335 patient C4P1, before first course of MP, B cells tissue: peripheral blood patient id: C4P1 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 5.3 cells per ml: 336000 purity (%): 96.3 rna integrity number: 9.4 age (years): 45 Sex: male body weight (in kg): 90 body size (in cm): 180 body mass index: 27.8 current smoker: yes study center: Rostock course of disease: CIS/RRMS disease duration (years): 13 number of relapses in the past 2 years: 0 duration since last relapse (months): 166 edss score: 3.5 disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 5 side effects to mp: hyperhidrosis 2.80214
GSM8083336 patient C4P1, after first course of MP, B cells tissue: peripheral blood patient id: C4P1 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 6.9 cells per ml: 1417500 purity (%): 96.1 rna integrity number: 8.7 age (years): 45 Sex: male body weight (in kg): 90 body size (in cm): 180 body mass index: 27.8 current smoker: yes study center: Rostock course of disease: CIS/RRMS disease duration (years): 13 number of relapses in the past 2 years: 0 duration since last relapse (months): 166 edss score: 3.5 disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 5 side effects to mp: hyperhidrosis 2.89479
GSM8083337 patient C4P2, before first course of MP, B cells tissue: peripheral blood patient id: C4P2 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: NA cells per ml: 493500 purity (%): 94.2 rna integrity number: 8.2 age (years): 54 Sex: female body weight (in kg): 93 body size (in cm): 173 body mass index: 31.1 current smoker: no study center: Rostock course of disease: SPMS disease duration (years): 20 number of relapses in the past 2 years: 1 duration since last relapse (months): 11 edss score: 7.5 disease-modifying therapy: none number of other medications taken: 3 neurological dysfunction: NA fs: bladder or bowel: yes fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: no fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 6 side effects to mp: none 2.74481
GSM8083338 patient C4P2, after first course of MP, B cells tissue: peripheral blood patient id: C4P2 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 0.4 cells per ml: 236250 purity (%): 42.7 rna integrity number: 8.1 age (years): 54 Sex: female body weight (in kg): 93 body size (in cm): 173 body mass index: 31.1 current smoker: no study center: Rostock course of disease: SPMS disease duration (years): 20 number of relapses in the past 2 years: 1 duration since last relapse (months): 11 edss score: 6.5 disease-modifying therapy: none number of other medications taken: 3 neurological dysfunction: NA fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 6 side effects to mp: none 2.67915

ID GSE4386
Title Transcriptomics in cardiac surgery
Organism Homo sapiens
GSM Sample info Characteristics Value
GSM99229 H01_S_B1 male CABG patient, atrial tissue baseline before CABG surgery 4.505895609
GSM99235 H01_S_B2 male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery 4.526379023
GSM99239 H02_P_B1 male CABG patient, atrial tissue baseline before CABG surgery 4.4985796
GSM99241 H02_P_B2 male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery 4.56624226
GSM99244 H03_P_B1 male CABG patient, atrial tissue baseline before CABG surgery 4.52705258
GSM99246 H03_P_B2 male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery 4.705879666
GSM99247 H04_P_B1 male CABG patient, atrial tissue, baseline before CABG surgery 4.474107309
GSM99249 H04_P_B2 male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery 4.502280606
GSM99252 H05_S_B1 male CABG patient, atrial tissue, baseline before CABG surgery 4.425056595
GSM99253 H05_S_B2 male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery 4.388447247
GSM99255 H06_S_B1 male CABG patient, atrial tissue, baseline before CABG surgery 4.603716229
GSM99257 H06_S_B2 male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery 4.589849758
GSM99258 H07_S_B1 male CABG patient, atrial tissue, baseline before CABG surgery 4.389837774
GSM99259 H07_S_B2 male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery 4.495330881
GSM99261 H08_P_B1 male CABG patient, atrial tissue, baseline before CABG surgery 4.36024333
GSM99265 H08_P_B2 male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery 4.483425646
GSM99268 H09_S_B1 male CABG patient, atrial tissue, baseline before CABG surgery 4.445143631
GSM99271 H09_S_B2 male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery 4.480465092
GSM99274 H10_P_B1 male CABG patient, atrial tissue, baseline before CABG surgery 4.736555082
GSM99277 H10_P_B2 male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery 4.673360927
GSM99280 H11_S_B1 male CABG patient, atrial tissue, baseline before CABG surgery 4.264977347
GSM99282 H11_S_B2 male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery 4.326964322
GSM99285 H12_P_B1 male CABG patient, atrial tissue, baseline before CABG surgery 4.525559361
GSM99287 H12_P_B2 male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery 4.624727461
GSM99289 H13_S_B1 male CABG patient, atrial tissue, baseline before CABG surgery 4.447245637
GSM99290 H13_S_B2 male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery 4.606651251
GSM99291 H14_P_B1 male CABG patient, atrial tissue, baseline before CABG surgery 4.535479357
GSM99292 H14_P_B2 male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery 4.530665094
GSM99293 H15_S_B1 male CABG patient, atrial tissue, baseline before CABG surgery 4.512716773
GSM99294 H15_S_B2 male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery 4.695139792
GSM99295 H16_P_B1 male CABG patient, atrial tissue, baseline before CABG surgery 4.594282213
GSM99296 H16_P_B2 male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery 4.661916757
GSM99298 H17_S_B1 male CABG patient, atrial tissue, baseline before CABG surgery 4.409824172
GSM99299 H17_S_B2 male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery 4.469437888
GSM99301 H18_P_B1 male CABG patient, atrial tissue, baseline before CABG surgery 4.58449499
GSM99302 H18_P_B2 male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery 4.587622723
GSM99303 H19_P_B1 male CABG patient, atrial tissue, baseline before CABG surgery 4.439364288
GSM99304 H19_P_B2 male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery 4.512745904
GSM99305 H20_S_B1 male CABG patient, atrial tissue, baseline before CABG surgery 4.411459588
GSM99306 H20_S_B2 male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery 4.393736959

ID GSE56256
Title Influence of hexafluoro-2-propanol (HFIP) on lipopolysaccharides-induced inflammation in human microvascular endothelial cells of the lung
Organism Homo sapiens
GSM Sample info Characteristics Value
GSM1357752 7_HFIP cell type: Human microvascular endothelial cells (HMVEC) exposed to: HFIP 8mmol/L over a time period of 6 hrs 43.135315
GSM1357753 8_HFIP cell type: Human microvascular endothelial cells (HMVEC) exposed to: HFIP 8mmol/L over a time period of 6 hrs 132.52265
GSM1357754 9_HFIP cell type: Human microvascular endothelial cells (HMVEC) exposed to: HFIP 8mmol/L over a time period of 6 hrs 54.120045000000005
GSM1357755 4_LPS cell type: Human microvascular endothelial cells (HMVEC) exposed to: LPS 20mcg/mL over a time period of 6 hrs 24.710575
GSM1357756 5_LPS cell type: Human microvascular endothelial cells (HMVEC) exposed to: LPS 20mcg/mL over a time period of 6 hrs 162.13975
GSM1357757 6_LPS cell type: Human microvascular endothelial cells (HMVEC) exposed to: LPS 20mcg/mL over a time period of 6 hrs 36.572705
GSM1357758 11_LPS-HFIP cell type: Human microvascular endothelial cells (HMVEC) exposed to: LPS 20mcg/mL and HFIP 8mmol/L over a time period of 6 hrs 31.78557
GSM1357759 12_LPS-HFIP cell type: Human microvascular endothelial cells (HMVEC) exposed to: LPS 20mcg/mL and HFIP 8mmol/L over a time period of 6 hrs 26.85181
GSM1357760 1_PBS cell type: Human microvascular endothelial cells (HMVEC) exposed to: PBS (control) over a time period of 6 hrs 38.979925
GSM1357761 2_PBS cell type: Human microvascular endothelial cells (HMVEC) exposed to: PBS (control) over a time period of 6 hrs 36.08957
GSM1357762 3_PBS cell type: Human microvascular endothelial cells (HMVEC) exposed to: PBS (control) over a time period of 6 hrs 40.857704999999996

ID GSE59526
Title Affymetrix Chip data of the transcriptome of human clinical study for acupuncture mechanisms on rheumatoid arthritis
Organism Homo sapiens
GSM Sample info Characteristics Value
GSM1438864 Peripheral blood mononuclear cells from AP group, Patient 2 before therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 53 treatment group: acupuncture+methotrexate time point: before therapy patient id: 2 2.628523855
GSM1438865 Peripheral blood mononuclear cells from AP group, Patient 3 before therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 48 treatment group: acupuncture+methotrexate time point: before therapy patient id: 3 3.580574846
GSM1438866 Peripheral blood mononuclear cells from AP group, Patient 6 before therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 36 treatment group: acupuncture+methotrexate time point: before therapy patient id: 6 8.173531437
GSM1438867 Peripheral blood mononuclear cells from AP group, Patient 8 before therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 60 treatment group: acupuncture+methotrexate time point: before therapy patient id: 8 4.796946103
GSM1438868 Peripheral blood mononuclear cells from AP group, Patient 9 before therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 31 treatment group: acupuncture+methotrexate time point: before therapy patient id: 9 5.868654158
GSM1438869 Peripheral blood mononuclear cells from MTX group, Patient 4 before therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 61 treatment group: methotrexate time point: before therapy patient id: 4 5.198933625
GSM1438870 Peripheral blood mononuclear cells from MTX group, Patient 5 before therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 49 treatment group: methotrexate time point: before therapy patient id: 5 9.08511857
GSM1438871 Peripheral blood mononuclear cells from MTX group, Patient 7 before therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 35 treatment group: methotrexate time point: before therapy patient id: 7 2.687775397
GSM1438872 Peripheral blood mononuclear cells from Patient 1 after 2 weeks acupuncture therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 64 treatment group: acupuncture+methotrexate time point: after 2 weeks therapy patient id: 1 3.627066387
GSM1438873 Peripheral blood mononuclear cells from Patient 3 after 2 weeks acupuncture therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 48 treatment group: acupuncture+methotrexate time point: after 2 weeks therapy patient id: 3 3.87653361
GSM1438874 Peripheral blood mononuclear cells from Patient 1 after 3 months acupuncture therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 64 treatment group: acupuncture+methotrexate time point: after 3 months therapy patient id: 1 2.317964628
GSM1438875 Peripheral blood mononuclear cells from Patient 2 after 3 months acupuncture therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 53 treatment group: acupuncture+methotrexate time point: after 3 months therapy patient id: 2 3.279870794
GSM1438876 Peripheral blood mononuclear cells from Patient 6 after 3 months acupuncture therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 36 treatment group: acupuncture+methotrexate time point: after 3 months therapy patient id: 6 20.95167144
GSM1438877 Peripheral blood mononuclear cells from Patient 8 after 3 months acupuncture therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 60 treatment group: acupuncture+methotrexate time point: after 3 months therapy patient id: 4.05851359
GSM1438878 Peripheral blood mononuclear cells from Patient 9 after 3 months acupuncture therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 31 treatment group: acupuncture+methotrexate time point: after 3 months therapy patient id: 9 2.843309445
GSM1438879 Peripheral blood mononuclear cells from Patient 4 after 3 months MTX therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 61 treatment group: methotrexate time point: after 3 months therapy patient id: 4 2.667465958
GSM1438880 Peripheral blood mononuclear cells from Patient 5 after 3 months MTX therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 49 treatment group: methotrexate time point: after 3 months therapy patient id: 5 4.04212612
GSM1438881 Peripheral blood mononuclear cells from Patient 7 after 3 months MTX therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 35 treatment group: methotrexate time point: after 3 months therapy patient id: 7 3.822105276